PACAP (1-27), human, ovine, rat

• UNSPSC Description:

  PACAP (1-27), human, ovine, rat (PACAP 1-27) is the N-terminal fragment of PACAP-38, and is a potent PACAP receptor antagonist with IC50s of 3 nM, 2 nM and 5 nM for rat PAC1, rat VPAC1 and human VPAC2, respectively[1].

• Target Antigen:

  PACAP Receptor

• Type:

  Peptides

• Related Pathways:

  GPCR/G Protein

• Applications:

  Metabolism-protein/nucleotide metabolism

• Field of Research:

  Metabolic Disease; Neurological Disease

• Assay Protocol:

  https://www.medchemexpress.com/PACAP__1-27_,_human,_ovine,_rat.html

• Purity:

  99.79

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  O=C(N[C@@H](CO)C(N[C@@H](CC(O)=O)C(NCC(N[C@@H]([C@@H](C)CC)C(N[C@@H](CC1=CC=CC=C1)C(N[C@@H]([C@H](O)C)C(N[C@@H](CC(O)=O)C(N[C@@H](CO)C(N[C@@H](CC2=CC=C(C=C2)O)C(N[C@@H](CO)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CC3=CC=C(C=C3)O)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCCCN)C(N[C@@H](CCC(N)=O)C(N[C@@H](CCSC)C(N[C@@H](C)C(N[C@@H](C(C)C)C(N[C@@H](CCCCN)C(N[C@@H](CCCCN)C(N[C@@H](CC4=CC=C(C=C4)O)C(N[C@@H](CC(C)C)C(N[C@@H](C)C(N[C@@H](C)C(N[C@@H](C(C)C)C(N[C@@H](CC(C)C)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)[C@H](CC5=CNC=N5)N

• Molecular Weight:

  3147.66

• References & Citations:

  [1]Gourlet P, et al. Fragments of pituitary adenylate cyclase activating polypeptide discriminate between type I and II recombinant receptors. Eur J Pharmacol. 1995 Dec 4;287(1):7-11.|[2]Schäfer H, et al. Structural motifs of pituitary adenylate cyclase-activating polypeptide (PACAP) defining PAC1-receptor selectivity. Regul Pept. 1999 Feb 5;79(2-3):83-92.|[3]Lindén A, et al. Inhibition of bronchoconstriction by pituitary adenylate cyclase activating polypeptide (PACAP 1-27) in guinea-pigs in vivo. Br J Pharmacol. 1995 Jul;115(6):913-6.Cell Metab. 2022 Nov 11;S1550-4131(22)00490-9.|Nature. 2024 Mar;627(8002):149-156.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)

• Clinical Information:

  No Development Reported

• CAS Number:

  127317-03-7